Haleon PLC Sponsored ADR $HLN Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC lowered its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 26.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 225,407 shares of the company’s stock after selling 80,376 shares during the period. HighTower Advisors LLC’s holdings in Haleon were worth $2,022,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HLN. Bank of America Corp DE boosted its position in shares of Haleon by 116.7% during the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock worth $128,423,000 after acquiring an additional 6,669,923 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Haleon by 3,031.5% during the second quarter. Acadian Asset Management LLC now owns 5,384,661 shares of the company’s stock worth $55,813,000 after purchasing an additional 5,212,711 shares during the last quarter. ABC Arbitrage SA lifted its stake in Haleon by 159.4% during the third quarter. ABC Arbitrage SA now owns 2,727,350 shares of the company’s stock worth $24,464,000 after purchasing an additional 1,675,889 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Haleon by 3,548.4% in the second quarter. BNP Paribas Financial Markets now owns 1,684,968 shares of the company’s stock valued at $17,473,000 after purchasing an additional 1,638,784 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Haleon by 15.5% in the second quarter. JPMorgan Chase & Co. now owns 8,776,686 shares of the company’s stock valued at $91,014,000 after purchasing an additional 1,174,813 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Up 2.7%

HLN stock opened at $11.06 on Friday. The stock has a market capitalization of $49.23 billion, a PE ratio of 28.35 and a beta of 0.19. The company has a fifty day moving average of $10.46 and a 200-day moving average of $9.82. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87. Haleon PLC Sponsored ADR has a one year low of $8.71 and a one year high of $11.42.

Haleon Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be issued a $0.1307 dividend. This represents a yield of 251.0%. The ex-dividend date of this dividend is Friday, April 10th. Haleon’s payout ratio is currently 28.21%.

Wall Street Analyst Weigh In

HLN has been the subject of several recent analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. Deutsche Bank Aktiengesellschaft cut shares of Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Morgan Stanley restated an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.